

Richter signed a distribution and supply agreement with Allergan

Budapest, Hungary – 19 January 2017 – Gedeon Richter Plc. (hereinafter: “Richter”) today announced that it has entered into a distribution and supply agreement with Allergan plc (hereinafter: “Allergan”) to commercialize its levonorgestrel releasing Intrauterine System (IUS) in Western Europe and in other European countries under the trademark of Levosert®. National marketing authorizations have been already granted in Western and Northern Europe and the product has been launched by Allergan in a number of these countries. The product is already marketed by Richter in most of the Central and Eastern European countries according to an agreement established with Uteron Pharma in 2011.

Under the terms of the agreement Richter shall make an upfront payment upon signature of the contract. In addition, further sales related royalties and milestone payments will become payable to Allergan subsequent to the launch of the product.

“This agreement is considered as a further step to enhance our existing branded female healthcare franchise worldwide, being a paramount strategic initiative for our Company”, said Erik Bogsch, Managing Director of Gedeon Richter Plc. “The addition of this IUS to our currently available products provides Richter the unique opportunity to enhance its contraceptive franchise.”

About Gedeon Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Having reached a market capitalisation of EUR 3.3 billion (US\$ 3.6 billion) by the end of 2015, Richter's consolidated sales were approximately EUR 1.2 billion (US\$ 1.3 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's healthcare, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's healthcare field worldwide. Richter is also active in biosimilar product development.

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 15,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what it is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

For more information:

Investors:

Katalin Ördög: +36 1 431 5680

Media:

Zsuzsa Beke: +36 1 431 4888